Status in Israel
Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Tablets 120 X 250 mg |
|
55637 |
Related information
Dosage
Intended for male patients only. 1,000 mg (four 250mg tablets) once daily in combination with prednisone.
Indications
The drug CYP inhibitor and it is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
Contra-Indications
Hypersensitivity to active substance or any of its excipients. Use in female patients. Severe hepatic impairment.
Manufacturer
Teva Pharmaceutical Industries Ltd, Israel
Licence holder
